Cytek Biosciences (CTKB) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$206.7M

Revenue (quarter)

$48.1M

Revenue growth (year over year)

+5.57%

Gross profit (trailing twelve months)

$110.0M

Gross margin

53.23%

Net income (trailing twelve months)

−$80.6M

Net income (quarter)

−$12.2M

Net income growth (year over year)

−117.77%

Net margin

−38.98%

Return on equity

−23.04%

EPS (trailing twelve months)

−$0.63

Book value per share

$2.48

P/E (trailing twelve months)

—

Price to book

2.16

Debt to assets

27.96%

Payout ratio

—

Dividend yield

—

Company profile

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.

• Is Cytek Biosciences (CTKB) profitable?

  No. Cytek Biosciences reported a net loss of $80.6M over the trailing twelve months.

• How much revenue does Cytek Biosciences (CTKB) make?

  Cytek Biosciences generated $206.7M in revenue over the trailing twelve months, up 5.57% year over year.

• How do I buy stock in Cytek Biosciences (CTKB)?

  CTKB trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.